News & Updates
Filter by Specialty:
Dose-capping chemoradiotherapy tied to higher recurrence in rectal cancer
The risk of disease recurrence is increased among rectal cancer patients treated with dose-capped chemoradiotherapy (CRT), reveals a study. In addition, excessive toxicity has occurred among those dosed by actual body surface area (BSA) compared to patients in the dose-capped group.
Dose-capping chemoradiotherapy tied to higher recurrence in rectal cancer
24 Oct 2021
Novel score predicts survival, radiological response in HCC
The novel CRAFITY score—which takes into account C-reactive protein (CRP), alpha-foetoprotein (AFP), and immunotherapy—can be used to reliably assess survival and radiological response in hepatocellular carcinoma (HCC), a recent study has found. Future validation is needed before CRAFITY can be deployed to the clinics.
Novel score predicts survival, radiological response in HCC
24 Oct 2021
Negative upper endoscopy findings in GERD signal lower upper gastrointestinal cancer risk
Negative upper endoscopy findings in patients with gastroesophageal reflux disease (GERD) indicate lower risk of developing upper gastrointestinal cancer, a new study has found.
Negative upper endoscopy findings in GERD signal lower upper gastrointestinal cancer risk
21 Oct 2021
NLR, PLR improve early detection of second primary cancer after gastric cancer
Combining the neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios with existing diagnostic methods helps improve early detection of second primary cancers (SPC) after initial gastric cancer (GC), a recent study has found.
NLR, PLR improve early detection of second primary cancer after gastric cancer
20 Oct 2021
DOACs on par with LMWH at preventing VTE in cancer patients
Cancer patients receiving either low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) show comparable frequency of venous thromboembolism (VTE), reports a recent study.
DOACs on par with LMWH at preventing VTE in cancer patients
19 Oct 2021
CDK4/6 inhibitors + fulvestrant improve OS in HR-positive, HER2-negative advanced breast cancer
The addition of a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor to fulvestrant provides a consistent benefit in overall survival (OS) in patients with hormone receptor (HR)–positive, HER2-negative, advanced or metastatic breast cancer in first-, second- and later-line settings and in most clinicopathological subgroups of interest, results of a US FDA pooled analysis of have shown.
CDK4/6 inhibitors + fulvestrant improve OS in HR-positive, HER2-negative advanced breast cancer
18 Oct 2021
Lenalidomide plus R-CHOP effective for untreated DLBCL patients
Combining lenalidomide with R-CHOP* (R2CHOP) yields durable and high rates of treatment response in untreated patient with diffuse large B-cell lymphoma (DLBCL), a recent study has found.
Lenalidomide plus R-CHOP effective for untreated DLBCL patients
16 Oct 2021
Second-line selective internal radiotherapy slows colorectal liver metastases progression
Administering a device-based selective internal radiation therapy, in addition to systemic treatment in the second-line setting, extends time to progression in colorectal liver metastases patients, as shown in the phase III EPOCH trial.
Second-line selective internal radiotherapy slows colorectal liver metastases progression
14 Oct 2021
KEYNOTE unlocks immunotherapy OS benefit in metastatic TNBC, effective in early disease
Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has a dismal prognosis. However, immunotherapy survival benefits reported in KEYNOTE-522 and KEYNOTE-355 trials bring new hope for this indication. [Ann Oncol 2021;32:994-1004]